BR0317003A - Derivados de imidazol como inibidores do fator xa - Google Patents
Derivados de imidazol como inibidores do fator xaInfo
- Publication number
- BR0317003A BR0317003A BR0317003-9A BR0317003A BR0317003A BR 0317003 A BR0317003 A BR 0317003A BR 0317003 A BR0317003 A BR 0317003A BR 0317003 A BR0317003 A BR 0317003A
- Authority
- BR
- Brazil
- Prior art keywords
- factor
- compounds
- formula
- inhibitors
- imidazole derivatives
- Prior art date
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title abstract 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title abstract 2
- 150000002460 imidazoles Chemical class 0.000 title 1
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical class C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 229940012414 factor viia Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02027120A EP1426364A1 (en) | 2002-12-04 | 2002-12-04 | Imidazole-derivatives as factor Xa inhibitors |
| EP03011307A EP1479674A1 (en) | 2003-05-19 | 2003-05-19 | Imidiazole-derivatives as factor xa inhibitors |
| PCT/EP2003/012996 WO2004050636A2 (en) | 2002-12-04 | 2003-11-20 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317003A true BR0317003A (pt) | 2005-10-25 |
Family
ID=32471891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317003-9A BR0317003A (pt) | 2002-12-04 | 2003-11-20 | Derivados de imidazol como inibidores do fator xa |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1569927B1 (enExample) |
| JP (1) | JP4504820B2 (enExample) |
| AR (1) | AR042261A1 (enExample) |
| AT (1) | ATE401322T1 (enExample) |
| AU (1) | AU2003285336B2 (enExample) |
| BR (1) | BR0317003A (enExample) |
| CA (1) | CA2507624A1 (enExample) |
| DE (1) | DE60322254D1 (enExample) |
| MX (1) | MXPA05005498A (enExample) |
| PE (1) | PE20040700A1 (enExample) |
| TW (1) | TW200504027A (enExample) |
| WO (1) | WO2004050636A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2006047415A2 (en) | 2004-10-26 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Factor xa compounds |
| AU2005321091B2 (en) | 2004-12-30 | 2012-04-12 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases |
| EP1968579A1 (en) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| EP2257546B1 (en) | 2008-02-21 | 2012-08-15 | Merck Sharp & Dohme Corp. | Functionally selective alpha2c adrenoreceptor agonists |
| EP2593447B1 (de) | 2010-07-15 | 2016-08-17 | Bayer Intellectual Property GmbH | 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel |
| CN114105881B (zh) * | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| WO2001032628A1 (en) * | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Pharma Company | Cyano compounds as factor xa inhibitors |
| WO2002000651A2 (en) * | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
-
2003
- 2003-11-20 JP JP2004570676A patent/JP4504820B2/ja not_active Expired - Fee Related
- 2003-11-20 CA CA002507624A patent/CA2507624A1/en not_active Abandoned
- 2003-11-20 AT AT03778324T patent/ATE401322T1/de not_active IP Right Cessation
- 2003-11-20 DE DE60322254T patent/DE60322254D1/de not_active Expired - Lifetime
- 2003-11-20 EP EP03778324A patent/EP1569927B1/en not_active Expired - Lifetime
- 2003-11-20 AU AU2003285336A patent/AU2003285336B2/en not_active Ceased
- 2003-11-20 BR BR0317003-9A patent/BR0317003A/pt unknown
- 2003-11-20 WO PCT/EP2003/012996 patent/WO2004050636A2/en not_active Ceased
- 2003-11-20 MX MXPA05005498A patent/MXPA05005498A/es unknown
- 2003-11-24 PE PE2003001185A patent/PE20040700A1/es not_active Application Discontinuation
- 2003-12-02 TW TW092133762A patent/TW200504027A/zh unknown
- 2003-12-02 AR ARP030104430A patent/AR042261A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1569927B1 (en) | 2008-07-16 |
| WO2004050636A3 (en) | 2004-10-14 |
| TW200504027A (en) | 2005-02-01 |
| PE20040700A1 (es) | 2004-11-25 |
| AU2003285336B2 (en) | 2009-11-26 |
| JP2006514093A (ja) | 2006-04-27 |
| MXPA05005498A (es) | 2005-07-25 |
| AR042261A1 (es) | 2005-06-15 |
| EP1569927A2 (en) | 2005-09-07 |
| JP4504820B2 (ja) | 2010-07-14 |
| ATE401322T1 (de) | 2008-08-15 |
| CA2507624A1 (en) | 2004-06-17 |
| DE60322254D1 (de) | 2008-08-28 |
| AU2003285336A1 (en) | 2004-06-23 |
| WO2004050636A2 (en) | 2004-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0317659A (pt) | Derivados de pirazol como inibidores de fator xa | |
| BR0214396A (pt) | Indol-2-carboxamidas como inibidores de fator xa | |
| BR0116473A (pt) | Derivados de oxibenzamidas como inibidores de fator xa | |
| BRPI0508048A (pt) | derivados de pirrol como inibidores do fator xa | |
| UY28325A1 (es) | Nuevos derivados de indol como inhibidores del factor xa | |
| PE20050153A1 (es) | DERIVADOS DE INDAZOL COMO INHIBIDORES DEL FACTOR Xa | |
| BR0115938A (pt) | Derivados de guanidina e amidina com inibidores do fator xa | |
| BR0111264A (pt) | Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização | |
| BRPI0508320A (pt) | derivados de beta-aminoácido como inibidores do fator xa | |
| BR0015186A (pt) | N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as | |
| BR0011461A (pt) | Inibidores do fator viia | |
| BR0317003A (pt) | Derivados de imidazol como inibidores do fator xa | |
| PE20050154A1 (es) | DERIVADOS DE TRIAZOL COMO INHIBIDORES DEL FACTOR Xa | |
| BRPI0410446A (pt) | derivados de benzimidazol como inibidores de fator xa | |
| BRPI0410429A (pt) | derivados de azaindol como inibidores do fator xa | |
| JO2467B1 (en) | New indole derivatives as an inhibitor of Xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
| B15L | Others concerning applications: renumbering |
Free format text: RENUMERADO PARA PI0310116-9 |